Table 1.
Patients and disease characteristics at the time of initial presentation on various TKI modalities.
| Imatinib 400 (n=68) | Imatinib 800 (n=200) | Dasatinib (n=106) | Nilotinib (n=108) | Overall (n=482) | |
|---|---|---|---|---|---|
| Median age, yrs (Range) | 49 [18–79] | 48 [19–85] | 48 [18–86] | 50 [18–86] | 49 [18–86] |
| Sokal Risk, % | |||||
| Low | 69 | 63 | 73 | 74 | 69 |
| Intermediate | 28 | 28 | 21 | 20 | 24 |
| High | 3 | 9 | 4 | 7 | 7 |
| WBC count (K/μL) Median (Range) | 22 (2 – 277) | 27 (2 – 283) | 26 (1 – 193) | 40 (1 – 342) | 28 (1 – 342) |
| Hemoglobin (g/dL) Median (Range) | 13 (8 – 16) | 12 (6 – 17) | 12 (7 – 16) | 12 (8 – 16) | 12 (6 – 17) |
| Peripheral blood blasts (%) Median (Range) | 0 (0 – 2) | 0 (0 – 12) | 0 (0 – 5) | 0 (0 – 7) | 0 (0 – 12) |
| Platelets (K/μL) (%) Median (Range) | 367 (103 – 1043) | 346 (15 – 1476) | 333 (86 – 1906) | 315 (73 – 2928) | 343 (15 – 2928) |
| Serum LDH (IU/L) Median (Range) | 367 (103 – 1043) | 346 (15 – 1476) | 333 (86 – 1906) | 315 (73 – 2928) | 343 (15 – 2928) |
| Splenomegaly, n(%) Spleen size >10 cm | 3 (5) | 17 (8) | 4 (4) | 4 (4) | 29 (6) |
| Median follow up in months (Interquartile Range) | 144 (60) | 116 (26) | 55 (49) | 49 (34) | 90 (74.1) |